79 related articles for article (PubMed ID: 31933417)
1. Does sites of recurrence impact survival in secondary cytoreduction surgery for recurrent epithelial ovarian cancer?
Kumar S; Srinivasan A; Phillips A; Madhupriya R; Pascoe J; Nevin J; Elattar A; Balega J; Cummins C; Sundar S; Kehoe ST; Singh K
J Obstet Gynaecol; 2020 Aug; 40(6):849-855. PubMed ID: 31933417
[TBL] [Abstract][Full Text] [Related]
2. A comparison of outcomes following total and selective peritonectomy performed at the time of interval cytoreductive surgery for advanced serous epithelial ovarian, fallopian tube and primary peritoneal cancer - A study by INDEPSO.
Sinukumar S; Rajan F; Mehta S; Damodaran D; Zaveri S; Kammar P; Bhatt A
Eur J Surg Oncol; 2021 Jan; 47(1):75-81. PubMed ID: 30857879
[TBL] [Abstract][Full Text] [Related]
3. Prognostic factors and the role of primary debulking in operable stage IVB ovarian cancer with supraclavicular lymph node metastasis: a retrospective study in Chinese patients.
Quan C; Chen X; Wen H; Wu X; Li J
BMC Cancer; 2024 May; 24(1):565. PubMed ID: 38711015
[TBL] [Abstract][Full Text] [Related]
4. Serial cytoreductive surgery and survival outcomes in recurrent adult-type ovarian granulosa cell tumors.
How JA; Legarreta AF; Handley KF; Fellman B; Foster KI; Glassman D; Vuttaradhi VK; Brodsky AL; Lawson B; Frumovitz M; Westin SN; Ramondetta LM; Gershenson DM; Sood AK; Hillman RT
Am J Obstet Gynecol; 2024 May; 230(5):544.e1-544.e13. PubMed ID: 38191019
[TBL] [Abstract][Full Text] [Related]
5. Continuous improvement in primary Debulking surgery for advanced ovarian cancer: Do increased complete gross resection rates independently lead to increased progression-free and overall survival?
Tseng JH; Cowan RA; Zhou Q; Iasonos A; Byrne M; Polcino T; Polen-De C; Gardner GJ; Sonoda Y; Zivanovic O; Abu-Rustum NR; Long Roche K; Chi DS
Gynecol Oncol; 2018 Oct; 151(1):24-31. PubMed ID: 30126704
[TBL] [Abstract][Full Text] [Related]
6. Correlation between peritoneal cancer index and survival in advanced epithelial ovarian cancer with complete resection.
Sanson C; Roosen A; Faron M; Zaccarini F; Maulard A; Scherier S; Pautier P; Leary A; Chargari C; Espenel S; Genestie C; Morice P; Gouy S
Int J Gynecol Cancer; 2024 May; 34(5):730-737. PubMed ID: 38485223
[TBL] [Abstract][Full Text] [Related]
7. Supragastric lesser sac: an insidious site for surgical exploration during the debulking surgery in advanced ovarian cancer.
Chen Y; Sun Z; Cai S; Hu Y; Jiang R; Xiang L; Zang R
J Gynecol Oncol; 2024 May; 35(3):e25. PubMed ID: 38130134
[TBL] [Abstract][Full Text] [Related]
8. Evaluation of secondary cytoreduction surgery in platinum-resistant ovarian cancer patients within three-line recurrent: a multicenter, randomized controlled study.
Chen T; Xu J; Xia B; Wang H; Shen Y
J Gynecol Oncol; 2024 Jan; 35(1):e22. PubMed ID: 37945326
[TBL] [Abstract][Full Text] [Related]
9. Predictive value of the Adult Comorbidity Evaluation 27 on adverse surgical outcomes and survival in elderly with advanced epithelial ovarian cancer undergoing cytoreductive surgery.
Zhao M; Gao Y; Yang J; He H; Su M; Wan S; Feng X; Wang H; Cai H
Eur J Med Res; 2024 Mar; 29(1):179. PubMed ID: 38494480
[TBL] [Abstract][Full Text] [Related]
10. Involved-field radiation therapy for locoregionally recurrent ovarian cancer.
Brown AP; Jhingran A; Klopp AH; Schmeler KM; Ramirez PT; Eifel PJ
Gynecol Oncol; 2013 Aug; 130(2):300-5. PubMed ID: 23648467
[TBL] [Abstract][Full Text] [Related]
11. Association between the quantitative characteristics of dual-energy spectral CT and cytoreduction surgery outcome in patients with advanced epithelial ovarian cancers: A prospective observational study.
Xu X; Chen Y; Zhang X; Wang Y
Medicine (Baltimore); 2024 Mar; 103(10):e37437. PubMed ID: 38457565
[TBL] [Abstract][Full Text] [Related]
12. Multidisciplinary Surgical Approach to Increase Survival for Advanced Ovarian Cancer in a Tertiary Gynaecological Oncology Centre.
Mulligan K; Corry E; Donohoe F; Glennon K; Vermeulen C; Reid-Schachter G; Thompson C; Walsh T; Shields C; McCormack O; Conneely J; Khan MF; Boyd WD; McVey R; O'Brien D; Treacy A; Mulsow J; Brennan DJ
Ann Surg Oncol; 2024 Jan; 31(1):460-472. PubMed ID: 37875740
[TBL] [Abstract][Full Text] [Related]
13. A randomized controlled trial to compare short-term outcomes following infragastric and infracolic omentectomy at the time of primary debulking surgery for epithelial ovarian cancer with normal-appearing omentum.
Dong X; Yuan L; Zou R; Yao L
J Ovarian Res; 2024 Apr; 17(1):85. PubMed ID: 38641834
[TBL] [Abstract][Full Text] [Related]
14. Impact of Ovarian Cancer Surgery Volume on Overall and Progression-Free Survival: A Population-Based Retrospective National French Study.
Prost P; Duraes M; Georgescu V; Rebel L; Mercier G; Rathat G
Ann Surg Oncol; 2024 May; 31(5):3269-3279. PubMed ID: 38393461
[TBL] [Abstract][Full Text] [Related]
15. First external validity study of the Fagotti score in ovarian cancer.
Sarah A; Mathieu L; Henri A; Marcos B; Geoffroy C; Pauline C; Tristan G; Cyrille H; Yohan K; Martin K; Lise L; Lobna O; Émilie R; Vincent L; Guillaume L
Sci Rep; 2024 May; 14(1):12133. PubMed ID: 38802436
[TBL] [Abstract][Full Text] [Related]
16. Exploring variations in ovarian cancer survival by age and stage (ICBP SurvMark-2): A population-based study.
Cabasag CJ; Butler J; Arnold M; Rutherford M; Bardot A; Ferlay J; Morgan E; Møller B; Gavin A; Norell CH; Harrison S; Saint-Jacques N; Eden M; Rous B; Nordin A; Hanna L; Kwon J; Cohen PA; Altman AD; Shack L; Kozie S; Engholm G; De P; Sykes P; Porter G; Ferguson S; Walsh P; Trevithick R; Tervonen H; O'Connell D; Bray F; Soerjomataram I
Gynecol Oncol; 2020 Apr; 157(1):234-244. PubMed ID: 32005583
[TBL] [Abstract][Full Text] [Related]
17. Quaternary and beyond cytoreduction: An updated and expanded analysis.
Manning-Geist BL; Chi DS; Long Roche K; Zivanovic O; Sonoda Y; Gardner GJ; O'Cearbhaill RE; Abu-Rustum NR; Leitao MM
Gynecol Oncol Rep; 2021 Aug; 37():100851. PubMed ID: 34485661
[TBL] [Abstract][Full Text] [Related]
18. Outcomes of secondary cytoreductive surgery in patients with platinum-sensitive recurrent ovarian cancer progressed after prior poly (adenosine diphosphate-ribose) polymerase inhibitors: A retrospective cohort study.
Zhao Y; Yuan H; Chen Y; Yao H; Li N; Wu L; Yuan G
Eur J Surg Oncol; 2024 May; 50(7):108383. PubMed ID: 38704898
[TBL] [Abstract][Full Text] [Related]
19. Laparoscopic Treatment of Bulky Nodes in Primary and Recurrent Ovarian Cancer: Surgical Technique and Outcomes from Two Specialized Italian Centers.
Daniele A; Rosso R; Ceccaroni M; Roviglione G; D'Ancona G; Peano E; Clignon V; Calandra V; Puppo A
Cancers (Basel); 2024 Apr; 16(9):. PubMed ID: 38730583
[TBL] [Abstract][Full Text] [Related]
20. Malignant Bowel Obstruction in Patients With Recurrent Ovarian Cancer.
Tran E; Spiceland C; Sandhu NP; Jatoi A
Am J Hosp Palliat Care; 2016 Apr; 33(3):272-5. PubMed ID: 25552305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
